{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:38:54Z","timestamp":1790678334383,"version":"4.1.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T00:00:00Z","timestamp":1549584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"DOI":"10.3389\/fmolb.2019.00003","type":"journal-article","created":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T04:19:52Z","timestamp":1549599592000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":57,"title":["Modulation of Enzyme Activity in the Kynurenine Pathway by Kynurenine Monooxygenase Inhibition"],"prefix":"10.3389","volume":"6","author":[{"given":"Robert S.","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma Carine","family":"Iradukunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamera","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Phillip","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,2,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bbi.2015.07.016","article-title":"Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms","volume":"51","author":"Aeinehband","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.neuro.2007.07.010","article-title":"Time-related changes in constitutive and inducible nitric oxide synthases in the rat striatum in a model of Huntington's disease","volume":"28","author":"Aguilera","year":"2007","journal-title":"Neurotoxicology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0014-5793(97)00627-3","article-title":"Cloning and functional expression of human kynurenine 3-monooxygenase","volume":"410","author":"Alberati-Giani","year":"1997","journal-title":"FEBS Lett"},{"key":"B4","volume-title":"Recent Advances in Tryptophan Research: Tryptophan and Serotonin Pathways","author":"Allegri","year":"2012"},{"key":"B5","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature12039","article-title":"Structural basis of kynurenine 3-monooxygenase inhibition","volume":"496","author":"Amaral","year":"2013","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1016\/j.bmcl.2016.10.058","article-title":"First molecular modeling report on novel arylpyrimidine kynurenine monooxygenase inhibitors through multi-QSAR analysis against Huntington's disease: a proposal to chemists! Bioorg. Medicinal Chem","volume":"26","author":"Amin","year":"2016","journal-title":"Lett."},{"key":"B7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1039\/cs9952400401","article-title":"Chemistry and neurochemistry of the kynurenine pathway of tryptophan metabolism","volume":"24","author":"Botting","year":"1995","journal-title":"Chem. Soc. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1046\/j.1432-1327.2000.01104.x","article-title":"Functional characterization and mechanism of action of recombinant human kynurenine 3-hydroxylase","volume":"267","author":"Breton","year":"2000","journal-title":"Eur. J. Biochem"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4137\/IJTR.S2097","article-title":"Kynurenine pathway metabolites in humans: disease and healthy states","volume":"2","author":"Chen","year":"2009","journal-title":"Int. J. Trypt. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1046\/j.1471-4159.1996.67020692.x","article-title":"Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase","volume":"67","author":"Chiarugi","year":"1996","journal-title":"J. Neurochem"},{"key":"B11","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1021\/ja0446395","article-title":"The pyridine ring of NAD is formed by a nonenzymatic pericyclic reaction","volume":"127","author":"Colabroy","year":"2005","journal-title":"J. Am. Chem. Soc"},{"key":"B12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/7355_2010_9","article-title":"Modulation of the kynurenine pathway for the potential treatment of neurodegenerative diseases","volume-title":"Neurodegenerative Diseases","author":"Courtney","year":"2010"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1002\/art.38715","article-title":"Treg cell function in rheumatoid arthritis is compromised by CTLA-4 promoter methylation resulting in a failure to activate the indoleamine 2,3-dioxygenase pathway","volume":"66","author":"Cribbs","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.pep.2006.07.024","article-title":"Heterologous expression and purification of kynurenine-3-monooxygenase from Pseudomonas fluorescens strain 17400","volume":"51","author":"Crozier","year":"2007","journal-title":"Prot. Exp. Purif"},{"key":"B15","doi-asserted-by":"publisher","first-page":"12420","DOI":"10.1021\/bi8010434","article-title":"Kynurenine 3-monooxygenase from Pseudomonas fluorescens: substrate-like inhibitors both stimulate flavin reduction and stabilize the flavin\u2013peroxo intermediate yet result in the production of hydrogen peroxide","volume":"47","author":"Crozier-Reabe","year":"2008","journal-title":"Biochemistry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"284","DOI":"10.4269\/ajtmh.2000.62.284","article-title":"Cerebrospinal fluid studies in children with cerebral malaria: an excitotoxic mechanism?","volume":"62","author":"Dobbie","year":"2000","journal-title":"Am. J. Trop. Med. Hyg"},{"key":"B17","doi-asserted-by":"publisher","first-page":"8762","DOI":"10.1021\/acs.jmedchem.5b00461","article-title":"Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway","volume":"58","author":"Dounay","year":"2015","journal-title":"J. Med. Chem"},{"key":"B18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.neuropharm.2016.05.020","article-title":"The kynurenine pathway in schizophrenia and bipolar disorder","volume":"112","author":"Erhardt","year":"2017","journal-title":"Neuropharmacology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1016\/j.bmcl.2012.04.002","article-title":"Ianthellamide A, a selective kynurenine-3-hydroxylase inhibitor from the Australian marine sponge Ianthella quadrangulata","volume":"22","author":"Feng","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1096\/fj.201700397RR","article-title":"Biochemistry and structural studies of kynurenine 3-monooxygenase reveal allosteric inhibition by Ro 61-8048","volume":"32","author":"Gao","year":"2018","journal-title":"FASEB J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3233\/JAD-170485","article-title":"Kynurenine pathway metabolites in alzheimer's disease","volume":"60","author":"Giil","year":"2017","journal-title":"J. Alz. Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"7266","DOI":"10.1021\/bi992997s","article-title":"3-Hydroxykynurenine and 3-Hydroxyanthranilic acid generate hydrogen peroxide and promote \u03b1-crystallin cross-linking by metal ion reduction","volume":"39","author":"Goldstein","year":"2000","journal-title":"Biochemistry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1111\/j.1742-4658.2012.08485.x","article-title":"Quinolinic acid, the inescapable neurotoxin","volume":"279","author":"Guillemin","year":"2012","journal-title":"FEBS J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/brain\/115.5.1249","article-title":"Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease","volume":"115","author":"Heyes","year":"1992","journal-title":"Brain"},{"key":"B25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1528-1157.1994.tb02428.x","article-title":"Kynurenine pathway metabolites in cerebrospinal fluid and serum in complex partial seizures","volume":"35","author":"Heyes","year":"1994","journal-title":"Epilepsia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/jb\/mvq099","article-title":"Dual role of the carboxyl-terminal region of pig liver L-kynurenine 3-monooxygenase: mitochondrial-targeting signal and enzymatic activity","volume":"148","author":"Hirai","year":"2010","journal-title":"J. Biochem"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.abb.2013.12.005","article-title":"Flavin dependent monooxygenases","volume":"544","author":"Huijbers","year":"2014","journal-title":"Arch. Biochem. Biophys"},{"key":"B28","doi-asserted-by":"publisher","first-page":"15827","DOI":"10.1038\/ncomms15827","article-title":"Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase","volume":"8","author":"Hutchinson","year":"2017","journal-title":"Nat. Comm"},{"key":"B29","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.chembiol.2018.01.008","article-title":"Structural basis for inhibitor-induced hydrogen peroxide production by kynurenine 3-monooxygenase","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Chem. Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.chembiol.2003.11.011","article-title":"NAD biosynthesis: identification of the tryptophan to quinolinate pathway in bacteria","volume":"10","author":"Kurnasov","year":"2003","journal-title":"Chem. Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.bbagen.2016.07.002","article-title":"Tryptophan 2, 3-dioxygenase and indoleamine 2, 3-dioxygenase 1 make separate, tissue-specific contributions to basal and inflammation-induced kynurenine pathway metabolism in mice","volume":"1860","author":"Larkin","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e14123","DOI":"10.1371\/journal.pone.0014123","article-title":"Characterisation of the expression of NMDA receptors in human astrocytes","volume":"5","author":"Lee","year":"2010","journal-title":"PLoS ONE"},{"key":"B33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.pneurobio.2015.12.009","article-title":"Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease","volume":"155","author":"Lim","year":"2017","journal-title":"Prog. Neurobiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1021\/jm8010806","article-title":"Crystal structure of the Homo sapiens kynureninase-3-hydroxyhippuric acid inhibitor complex: insights into the molecular basis of kynureninase substrate specificity","volume":"52","author":"Lima","year":"2008","journal-title":"J. Med. Chem"},{"key":"B35","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3389\/fimmu.2016.00246","article-title":"Current evidence for a role of the kynurenine pathway of tryptophan metabolism in multiple sclerosis","volume":"7","author":"Lovelace","year":"2016","journal-title":"Front. Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1177\/1087057113518069","article-title":"Lead discovery for human kynurenine 3-monooxygenase by high throughput RapidFire mass spectrometry","volume":"19","author":"Lowe","year":"2014","journal-title":"J. Biomol. Screen"},{"key":"B37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.4020","article-title":"Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis","volume":"22","author":"Mole","year":"2016","journal-title":"Nat. Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0006-291X(67)90123-4","article-title":"On the submitochondrial localization of L-kynurenine-3-hydroxylase","volume":"26","author":"Okamoto","year":"1967","journal-title":"Biochem. Biophys. Res. Comm"},{"key":"B39","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/0006-8993(82)91048-4","article-title":"An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid","volume":"247","author":"Perkins","year":"1982","journal-title":"Brain Res"},{"key":"B40","article-title":"Preparation of 2-cyano-3-oxo-3-benz[g]indazole-propanamides and analogs as kynurenine-3-hydroxylase inhibitors","author":"Pevarello","year":"1999"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.bmcl.2017.02.080","article-title":"Substrate and inhibitor specificity of kynurenine monooxygenase from Cytophaga hutchinsonii","volume":"27","author":"Phillips","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"B42","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.expneurol.2010.03.009","article-title":"Acute intrastriatal administration of quinolinic acid provokes hyperphosphorylation of cytoskeletal intermediate filament proteins in astrocytes and neurons of rats","volume":"224","author":"Pierozan","year":"2010","journal-title":"Exp. Neurol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e6344","DOI":"10.1371\/journal.pone.0006344","article-title":"The excitotoxin quinolinic acid induces tau phosphorylation in human neurons","volume":"4","author":"Rahman","year":"2009","journal-title":"PLoS ONE"},{"key":"B44","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jpsychires.2015.05.007","article-title":"Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: evidences from animal and human studies","volume":"68","author":"R\u00e9us","year":"2015","journal-title":"J. Psych. Res"},{"key":"B45","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1021\/jm970467t","article-title":"Synthesis and biochemical evaluation of N-(4-Phenylthiazol-2-yl)-benzenesulfonamides as high-affinity inhibitors of kynurenine 3- hydroxylase","volume":"40","author":"R\u00f6ver","year":"1997","journal-title":"J. Med. Chem"},{"key":"B46","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1471-4159.1993.tb05836.x","article-title":"Mechanism of Delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia","volume":"60","author":"Saito","year":"2006","journal-title":"J. Neurochem"},{"key":"B47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.expneurol.2005.07.004","article-title":"Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: implications for Huntington's disease","volume":"197","author":"Sapko","year":"2006","journal-title":"Exp. Neurol"},{"key":"B48","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/978-1-4939-7825-0_18","article-title":"Assessing and modulating kynurenine pathway dynamics in huntington's disease: focus on kynurenine 3-monooxygenase","volume-title":"Huntington's Disease","author":"Sathyasaikumar","year":"2018"},{"key":"B49","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrn3257","article-title":"Kynurenines in the mammalian brain: when physiology meets pathology","volume":"13","author":"Schwarcz","year":"2012","journal-title":"Nat. Rev. Neurosci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1021\/acsomega.7b02091","article-title":"Diclofenac identified as a kynurenine 3-monooxygenase binder and inhibitor by molecular similarity techniques","volume":"3","author":"Shave","year":"2018","journal-title":"ACS Omega"},{"key":"B51","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.drudis.2015.11.001","article-title":"Kynurenine-3-monooxygenase: a review of structure, mechanism, and inhibitors","volume":"21","author":"Smith","year":"2016","journal-title":"Drug Discov. Today"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1007\/s00018-017-2504-2","article-title":"Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases","volume":"74","author":"Song","year":"2017","journal-title":"Cell. Mol. Life Sci"},{"key":"B53","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0014-2999(96)00613-9","article-title":"(R,S)-3,4-Dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats","volume":"315","author":"Speciale","year":"1996","journal-title":"Eur. J. Pharmacol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0165-6147(00)01451-6","article-title":"Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection","volume":"21","author":"Stone","year":"2000","journal-title":"Trends Pharmacol. Sci"},{"key":"B55","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0014-2999(81)90587-2","article-title":"Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS","volume":"72","author":"Stone","year":"1981","journal-title":"Eur. J. Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1158\/2326-6066.CIR-14-0137","article-title":"Extensive profiling of the expression of the indoleamine 2, 3-dioxygenase 1 protein in normal and tumoral human tissues","volume":"3","author":"Th\u00e9ate","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1021\/jm501350y","article-title":"Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease","volume":"58","author":"Toledo-Sherman","year":"2015","journal-title":"J. Med. Chem"},{"key":"B58","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jbiotec.2006.03.044","article-title":"Flavoprotein monooxygenases, a diverse class of oxidative biocatalysts","volume":"124","author":"van Berkel","year":"2006","journal-title":"J. Biotechnol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nrd3793","article-title":"Kynurenines in the CNS: recent advances and new questions","volume":"12","author":"V\u00e9csei","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"B60","unstructured":"WilkinsonM.\n          University of EdinburghStructural Dynamics and Ligand Binding in Kynurenine-3-monooxygenase.2013"},{"key":"B61","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.cell.2011.05.020","article-title":"Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration","volume":"145","author":"Zwilling","year":"2011","journal-title":"Cell"}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmolb.2019.00003\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T04:20:00Z","timestamp":1549599600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmolb.2019.00003\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,8]]},"references-count":61,"alternative-id":["10.3389\/fmolb.2019.00003"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2019.00003","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,8]]},"article-number":"3"}}